A Phase I, Open Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Dose of Oral [14C]-IDV184001AN in Healthy Adult Male Participants
Latest Information Update: 15 Feb 2025
At a glance
- Drugs C4X 3256 (Primary)
- Indications Opioid-related disorders
- Focus Pharmacokinetics
- Sponsors Indivior
Most Recent Events
- 11 Aug 2023 New trial record
- 09 Aug 2023 Status changed from not yet recruiting to completed.